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Abstract: Among the members of the Arenaviridae family, Lassa virus and Junin virus 
generate periodic annual outbreaks of severe human hemorrhagic fever (HF) in endemic 
areas of West Africa and Argentina, respectively. Given the human health threat that 
arenaviruses represent and the lack of a specific and safe chemotherapy, the search for 
effective antiviral compounds is a continuous demanding effort. Since diverse host cell 
pathways and enzymes are used by RNA viruses to fulfill their replicative cycle, the 
targeting of a host process has turned an attractive antiviral approach in the last years for 
many unrelated virus types. This strategy has the additional benefit to reduce the serious 
challenge for therapy of RNA viruses to escape from drug effects through selection of 
resistant variants triggered by their high mutation rate. This article focuses on novel 
strategies to identify inhibitors for arenavirus therapy, analyzing the potential for antiviral 
developments of diverse host factors essential for virus infection. 
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Arenaviruses have turned in recent years a serious and increasing challenge for human public 
health, particularly in the Americas and Africa. Among the members of the Arenaviridae family,  
Lassa virus (LASV) and Junin virus (JUNV) generate periodic annual outbreaks of severe human 
hemorrhagic fever (HF) in endemic areas of West Africa and Argentina, respectively. LASV is the 
most prevalent and dangerous arenavirus, causing over 300,000 cases of Lassa fever per year and 
between 5,000 and 10,000 deaths [1]. By contrast, the incidence and severity of Argentine HF 
produced by JUNV is considerably lower, with 100–1,000 notified cases per year and a case-fatality 
rate about 15% in the absence of treatment [2]. Besides the critical situation in endemic areas, the high 
frequency of international air travels has also contributed to the importation of arenavirus HF cases 
into several urban areas around the world [3]. In addition to these two pathogens that represent the 
main health threat in the family, there are also four recognized arenaviruses, Sabiá, Guanarito, 
Machupo and Chapare virus, able to produce very sporadic cases of HF in Brazil, Venezuela and 
Bolivia, respectively. The prototype world-wide distributed arenavirus lymphocytic choriomeningitis 
virus (LCMV) can also infect humans, generally resulting in an asymptomatic course or a mild febrile 
illness sometimes associated with aseptic meningitis. However, LCMV is of considerable concern in 
pediatrics in cases of congenital infection [4] and also for immunocompromised patients, as recently 
shown in cases of fatal LCMV infection acquired through transplantation [5]. Furthermore, a 
continuous and extended emergence of new agents tentatively included as new members of 
Arenaviridae has occurred in the last decade either from accidental human infections causing a severe 
disease or as result of a systematic screening for virus or genome presence in the natural rodent 
reservoirs [6]. 
In spite of the health burden depicted by arenavirus infections, no safe and effective  
chemotherapy is currently available allowing for consider these pathologies as neglected viral diseases. 
Antiviral therapies are limited to the use of immune convalescent plasma with defined doses of  
JUNV-neutralizing antibodies, recommended for Argentine HF patients [2], or the guanosine analog 
ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (RIB), effective against Lassa fever by 
intravenous administration [7]. The use of these different treatments is a direct consequence of the 
different mechanism of protection associated to both arenavirus HF: protection in Argentine HF is 
based on induction of a strong humoral immune response [8] whereas in Lassa fever patient recovery 
is mainly associated to cell-mediated immune response with low antibody production [1]. However, 
several drawbacks are associated to both treatments: RIB is not efficient in advanced LASV infections 
and it can also induce adverse side effects such as thrombocytosis, anemia and birth defects [7–10] 
whereas plasma transfusion also is not effective in advanced cases and 10% of treated patients develop 
late neurological complications [2]. 
On this basis, there is an essential need for the development of novel therapeutic options against 
arenaviruses. Two mainly different approaches can be employed for viral chemotherapy development: 
the viral-target based approach, directed to block a virus encoded function, and the host-target based 
approach, aimed to inhibit any cellular function required for virus multiplication and/or pathogenesis. 
This article is focused on diverse cellular targets essential for virus infection and their perspectives for 
specific chemotherapy against arenaviruses. 
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2. Targeting Host Cell Factors: Advantages and Disadvantages  
Since licensed antiviral drugs in current use against other viruses target viral proteins, they are 
usually virus-specific and are prone to induce the fast appearance of viral resistant mutants. Resistance 
to viral inhibitors is a particularly more serious problem for therapy of clinically important RNA 
viruses, given their high mutation rates [11,12]. An alternative to mitigate this problem could be the 
development of drugs that affect host factors required for completion of virus replication cycle rather 
than directly pathogen encoded-factors. There are a number of processes for virus multiplication 
within the infected cell that involve cellular pathways and enzymes which have proven to be attractive 
targets for chemotherapeutic intervention against several unrelated viruses [13–16]. This approach is 
expected to establish a high barrier against viral escape from inhibition since it is not expectable that 
individual viral mutations will compensate for the loss of a required host factor. 
Besides the rare emergence of virus resistance, therapy by inhibiting cellular pathways provides a 
promising target for the development of broad-spectrum antivirals active against all the viruses of the 
same genus/family and even unrelated ones as many viruses may share a dependency on the same host 
function. Another advantage of cellular targets is the possibility to employ as antiviral agents the 
existing drugs licensed for other human disorders with defined safety-data profiles and available 
clinical-use histories, requiring only assessment for the new indirect use. 
On the other hand, targeting host factors might result sometimes in cytotoxic or other undesirable 
side-effects. To minimize this problem, inhibition needs to be directed with accuracy. In this aspect, 
the application of a host-based antiviral strategy appears to be more suitable for treatment of infections 
caused by pathogens associated with acute disease in humans, like HF arenaviruses, since the 
treatment time is limited and possible collateral effects may be minimized. 
An important limitation for evaluating antiviral strategies to combat HF arenaviruses is the 
requirement of BSL4 facilities to handle live infectious virus in the classical cytopathic effect/plaque 
reduction or virus yield inhibition assays. The development of reverse genetics systems for several 
members of the family, and recently in particular for JUNV [17,18] and LASV [19], has provided a 
very useful tool to discover and characterize antiviral drugs against arenaviruses, overcoming the 
biosafety restrictions since the production of infectious virus is not involved in these assays. In this 
context, retroviral pseudotypes bearing HF arenavirus glycoproteins and a luciferase reporter  
gene were used in high-throughput screening (HTS) of small molecule libraries for virus entry  
inhibitors [20,21]. A cell-based luciferase assay for rapid and quantitative evaluation of arenavirus 
budding inhibitors, suitable for HTS, was also developed in the last years [22] and it could be  
used in combination with siRNA-based screens against cellular genes illustrating the wide perspectives 
of these new technologies to improve and facilitate the identification of cellular targets for  
HF chemotherapy. 
To further support the rationale behind this antiviral strategy it is necessary to fully understand the 
significance and involvement of virus-cell interactions for proper viral infection. Novel automated 
genomics and proteomics together with bioinformatics have provided the tools to advance in the study 
of virus-host interactome in diverse pathogens [23–25]. Although there is still a little application of 
these technologies in arenaviruses [26–29], numerous reports for cell-based inhibitory strategies have 
been reported in the last years.  
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The main host factors or processes involved in arenavirus multiplication that have been analyzed as 
potential antiviral targets in vitro are summarized in Figure 1. Recent studies performed with  
JUNV on particular antiviral cell-targeted approaches with interesting perspectives will be further 
discussed here. 
Figure 1. Main host factors involved in arenavirus multiplication analyzed as potential 
antiviral targets. In an infected cell the cellular factors discussed in this article (IMPDH: 
inosine monophosphate dehydrogenase; CTPS: cytosine triphosphate synthetase; SAHH: 
S-adenosylhomocysteine hydrolase; OMPD: orotidylic acid decarboxylase; hnRNPs: 
heterogeneous nuclear ribonucleoproteins; PI3K/Akt: phosphatidylinositol-3-kinase/protein 
kinase B; MEK/ERK:mitogen-activated protein kinase/extracellular signal-regulated 
kinase; IRF-3: interferon regulatory factor 3; IKKε: inhibitor of nuclear factor kB  
kinase–related kinase; NF-κB: nuclear factor kappa B; RIG-I: retinoic acid-inducible gene I 
protein; PKR: protein kinase R; PML: promyelocytic leukemia protein; DG: dystroglycan; 
TfR: transferrin receptor) are indicated in red; other factors not discussed here (TSG101: 
tumor supresor gene 101; NMT: N-myristoyltransferase; SKI-1/S1P: subtilisin kexin 
isozyme-1/site 1 proprotein convertase; ATF-2: activating transcription factor 2; CREB: 
cAMP response element-binding [30–33] are in blue. 
 
3. Cellular Proteins Involved in RNA Synthesis or Processing  
3.1. Metabolism of Nucleosides  
In the context of cellular targets, one of the most explored to date is represented by cellular enzymes 
involved in the various metabolic pathways related to cell RNA synthesis and also engaged in virus 
RNA transcription and/or replication. Precisely RIB, the only antiviral in clinical use for HF caused by 
arenaviruses, is a prototypical example of this class of agents.  
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RIB is a guanosine analog which once inside the cell is phosphorylated first to RIB-5’-monophosphate 
and then to RIB-5’-triphosphate. The primary target for this compound is supposed to be the cellular 
enzyme inosine monophosphate dehydrogenase (IMPDH) that converts IMP to xanthosine 
monophosphate, a limiting step for de novo intracellular synthesis of guanosine nucleotides [34,35]. 
The blockade of IMPDH by RIB-5’-monophosphate decreased the intracellular GTP pool with the 
consequent reduction of viral RNA synthesis and virus yield, an effect reversed by exogenous addition 
of guanosine. However, multiple mechanisms of action have been proposed for RIB according to the 
virus/host system analyzed [36,37]. In the particular case of the arenaviruses, it is currently in 
discussion which is the real mode of action for RIB. There is evidence for JUNV and LASV that the 
mechanism of action of RIB is not mainly focused on IMPDH inhibition and additional proposed 
targets may involve the viral RNA polymerase or lethal mutagenesis [38–41].  
To overcome the shortcomings reported by the treatment of humans with RIB [9,10], other known 
IMPDH inhibitors were evaluated against different arenaviruses decades ago with variable results [42]. 
More recently, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and mycophenolic 
acid (MPA) were successfully tested against pathogenic arenaviruses showing greater antiviral potency 
and selectivity than RIB in vitro against JUNV and LASV with MPA as the most active inhibitor  
(IC50 values around 0.3 µg/mL) [38,39]. EICAR is a competitive inhibitor of IMPDH, whereas MPA is 
an uncompetitive inhibitor, and both compounds possess antiproliferative, immunosuppressive and 
antiviral properties [43,44]. JUNV and LASV inhibition was highly reversed by exogenous guanosine 
addition, indicating that antiviral activity is effectively associated with GTP depletion through IMPDH 
blockade as well as the high susceptibility of both HF arenavirus replication to this cellular pathway of 
inhibition [38,39]. 
Acridones are another class of compounds apparently related to cellular targets that have attracted 
attention in recent years for their wide range of biological properties. As for the antiviral properties of 
this class of compounds, several studies have shown the inhibitory action of acridone derivatives 
against DNA viruses such as herpes simplex virus and cytomegalovirus [45,46], Epstein-Barr  
virus [47] and adenovirus [48], as well as RNA viruses, including human immunodeficiency  
virus [49,50], bovine viral diarrhea virus [51] and hepatitis C [52,53]. The precise target and the mode 
of action of antiviral acridones are not clearly determined at present, although its predominant action 
seems to be centered on the synthesis of nucleic acids. It has been identified specific inhibitory activity 
against cellular enzymes such as DNA topoisomerase II [45,54] and IMPDH [55], and viral enzymes 
such as RNA helicase and RNA polymerase [53] as well as the ability to intercalate into the nucleic 
acid molecules, blocking the recognition and association of the enzyme to the modified molecule [56].  
With respect to arenaviruses, a screening of antiviral activity of diverse novel N-substituted 
acridone derivatives identified a group of 10-allyl-9(10H)-acridones as effective and very selective 
inhibitors of arenaviruses [57]. In particular, the 10-allyl-6-chloro-4-methoxy-9(10H)-acridone, 
designated 3f, was the most active compound that blocked replication of the pathogenic arenaviruses 
JUNV and LCMV as well as the four serotypes of dengue virus, another HF-causing RNA virus 
belonging to the family Flaviviridae. Mechanistic studies demonstrated that JUNV RNA synthesis was 
strongly inhibited and the addition of exogenous guanosine rescued the infectivity and viral RNA 
levels in a dose-dependent manner [39]. However, the guanosine reversal was partial, suggesting that 
GTP pool reduction may contribute to the inhibitory action but it is not the only operative mechanism: 
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a possible cellular target is represented by IMPDH whereas another still unidentified target, 
presumably viral, given the high selectivity of the compound, is also involved in the antiviral activity 
of the acridone against JUNV. Then, the possibility of a multiple effect on different targets, as reported 
for other acridones [53], turns promising perspectives for these agents in treatment of pathogenic 
arenavirus infections allowing a potent antiviral efficiency and less feasibility of generating resistance.  
Inhibitors of the biosynthetic pathway of pyrimidine nucleotides were also studied for anti-arenavirus 
activity. Compounds evaluated include cytidine analogs targeted to cytosine triphosphate synthetase 
(CTPS); carbanucleoside analogs which are inhibitors of the orotidylic acid decarboxylase (OMPD) 
which converts OMP to uridine monophosphate (UMP); and analogs of adenosine, most of them acting 
as inhibitors of S-adenosylhomocysteine hydrolase (SAHH), a key enzyme in the transmethylation to 
obtain the 5 ’cap of the mRNA [42,58,59]. However, the selectivity and effectiveness of these series of 
analogs were not very promising without showing appreciable advantages over RIB.  
The finding and characterization of molecules with broad-spectrum inhibitory action against viral 
RNA synthesis and minor cellular toxicity, as MPA and acridones above commented, represent novel 
promising alternatives for chemotherapy, although further in vivo evaluation is necessary to renew the 
consideration of this class of metabolic inhibitors against arenaviruses. 
3.2. Heterogeneous Nuclear Ribonucleoproteins 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) constitute a family of cellular RNA binding 
proteins which participate in RNA metabolic processes including mRNA splicing, nucleo-cytoplasmic 
trafficking, translation and turnover [60–62]. More than 20 hnRNPs have been characterized, called 
from hnRNP A1 to hnRNP U, and those belonging to the A/B group (hnRNP A1, A2/B1, A3) are 
among the smallest but most abundant hnRNPs [62]. In virus-infected cells, several hnRNPs are able 
to interact with viral components, RNA and proteins, modulating the multiplication of both DNA and 
RNA viruses. Several studies have proved the involvement of hnRNPs in different stages of viral 
replicative cycle, mainly in RNA synthesis, processing and translation [63–65]. In addition, several 
viruses induce changes in the level of expression and intracellular localization of these predominantly 
nuclear proteins and these alterations may facilitate viral replication and/or help the virus to counteract 
the host cell antiviral response [66,67]. 
There is some evidence about changes in hnRNP expression in arenavirus-infected cells that 
suggest a possible role of these cell factors on both viral infectivity and/or pathogenesis. Pichinde virus 
(PICV) infection of guinea pigs produces a pathology similar to Lassa fever in humans [68] and two 
viral variants, P2 (an attenuated virus that causes a mild infection) and P18 (a virulent virus that 
produces a severe HF in the guinea pig model), have been used to analyze cell signaling pathways and 
responses following infection of a murine macrophage-like cell line [28,29,69]. These studies 
identified several cellular signaling events which may be involved in PICV pathogenesis [28,29]. 
Virus-host interactions were further characterized by investigating the differential nuclear proteomes 
induced by the infection of these two PICV variants [69]. This analysis revealed that several hnRNPs 
(hnRNP A2/B1, hnRNP A3, hnRNP D0 and hnRNP L) exhibited substantial differential expression 
after infection with the attenuated or the virulent isolates. The subcellular localization of hnRNPs 
during infection was also investigated: at early times after infection only the attenuated variant P2 
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induced the cytoplasmic localization of hnRNP A2/B1, whereas hnRNP A1 remained predominantly 
nuclear for both P2 and P18. The results obtained with hnRNP A2/B1 are in accordance with previous 
data showing that at the initial stages of the infection cells infected with the virulent P18 variant 
resemble uninfected cells. Bowick et al., proposed either a failure in the activation of cell response or 
the suppression of this response after infection with the virulent virus, suggesting that virus-mediated 
alterations in hnRNP intracellular localization may be implicated in PICV pathogenesis [69].  
Infection of macaques with a lethal dose of LCMV also constitutes a model for LASV infection of 
humans [70] and the analysis of the expression of cell genes in a blood sample by using DNA 
microarray technology made possible the identification of genes that may serve as markers for disease 
progression and to gain insights into the molecular mechanisms triggering viral HF. Moreover, the 
comparison of the blood profiles after infection with the virulent LCMV strain WE or the  
non-virulent strain Armstrong [71] enabled the finding of genes that would be associated with viral  
pathogenesis [72]. This comparative study revealed that hnRNP C is downregulated in peripheral 
blood mononuclear cells isolated at early times after infection from rhesus macaques that were infected 
with WE [72]. It is interesting to note that virus-mediated changes in hnRNP C expression or 
localization would result in the inhibition of interferon (IFN) signaling since this hnRNP has been 
proved to be involved in phospho-STAT1 nuclear import, so a reduced level of hnRNP C in  
WE-infected cells may contribute to the severity of the infection [63,67]. 
The first report providing evidence about the importance of hnRNPs on JUNV replication was a 
comparative study of acute and persistent JUNV infections performed in Vero cell cultures [73]. 
Silencing of hnRNP A1 or hnRNP A2, by using small interfering RNAs (siRNAs), caused a decrease 
in JUNV protein synthesis and progeny virus production during acute infection. It was also 
demonstrated that acute JUNV infection does not affect hnRNP A/B levels of expression in 
comparison with uninfected cells and promotes the cytoplasmic accumulation of hnRNPA1. 
Cytoplasmic re-distribution of hnRNP A1 could also be detected in cells expressing the viral 
nucleoprotein and co-immunoprecipitation studies revealed the interaction between both proteins. 
Unlike the acute infection, persistently infected cultures do not produce infectious virus and exhibit a 
continuous synthesis of nucleoprotein, associated with blockage of the expression of the glycoprotein 
G1 and absence of cytopathic effect [74,75]. A marked diminishment in the hnRNP A/B expression 
was observed in persistently JUNV-infected cultures. Furthermore, overexpression of hnRNP A1 
allowed determining that cells persistently infected with JUNV do not induce hnRNP A1 cytoplasmic 
re-localization. These results indicate that hnRNP A1 would favor JUNV productive infection through 
the interaction with the nucleoprotein. On the other hand, JUNV non-productive persistent infection 
might involve downregulation of hnRNPs A/B, as well as changes in nucleo-cytoplasmic  
trafficking [73]. 
Despite much remains to be investigated about the relation between hnRNPs and arenavirus 
multiplication, persistence and pathogenesis, the data available to date indicate that these molecules 
can be considered as possible targets for antiviral therapy. However, it should be noted that hnRNPs do 
not always act as promoters of viral replication [63] and there are situations, such as hnRNP C 
downregulation by LCMV-WE infection mentioned above [72], in which a decrease in the level of 
expression of these cell factors could be associated with an increased viral pathogenicity.  
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4. Host Kinases 
4.1. Kinases and Signaling Pathways  
The phosphorylation of proteins, either viral or cellular, is an event of key importance that 
determines the fate of several features during the infection process related to viral multiplication and 
cell survival as well. Phosphorylation is a reversible post-translational modification that proteins may 
suffer in order to regulate stability, biological activity and interactions with other proteins. This 
process is chemically characterized by the addition of a negatively charged phosphate group to specific 
serine or threonine residues of the protein and may be accomplished by cellular or viral kinases. On the 
contrary, removal of phosphate groups from protein backbone is achieved through the action of 
phosphatases which, together with kinases, control most of the cellular signaling pathways involved  
in metabolism, transcription and translation, cell cycle, apoptosis, differentiation and immune  
response [76,77]. 
Solid evidence shows that viruses require the modulation of cell signaling pathways in order to 
ensure their successful replication. In this context, modulation of cell survival pathways is a key target 
for both DNA and RNA viruses as a strategy to temporarily overcome cell death and prolonging viral 
replication. The phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) is one of the major 
signaling pathways involved in cell survival, as well as proliferation, migration and apoptosis and, as 
such, has been shown to be widely involved in critical viral events like virus uptake, replication, 
translation and budding [78–80]. Several signaling pathways are also modulated by PI3K/Akt, among 
which are Bad, caspase-9, IKK, the Forkhead transcription factors, Mdm2, YAP, mTOR and the 
Forkhead box O (FoxO) transcription factors [81,82] and hence may be potentially regulated by 
viruses through PI3K modulation.  
It has been reported that JUNV is able to activate Akt-phosphorylation mediated by PI3K at an 
early stage of infection. This activation triggered during virus uptake would be necessary for an 
efficient recycling of transferrin receptor, main receptor involved in JUNV binding to the cell  
surface [83,84]. The inhibition of Akt phosphorylation by the PI3K inhibitor Ly294002 impaired virus 
production in different cell types indicating the essential role of PI3K/Akt signaling for JUNV 
infection. In view that PI3K/Akt activation is also involved in the stabilization of the mRNA encoding 
hnRNPA1 [85] and taking into account, as previously mentioned, the participation of this factor during 
JUNV replication [73], it is tempting to speculate that activation of this pathway may contribute in 
other stages of virus multiplication besides virus uptake.  
The participation of PI3K during the early stages of LASV and LCMV infection has also been 
described. For these Old World arenaviruses, which use α-dystroglycan as cellular receptor [86], the 
biosynthesis of lipid membrane phosphatidylinositol 3-phosphate (PI3P), mediated by PI3K, would be 
necessary to support the formation of multivesicular bodies, mechanism employed by these viruses to 
invade host cells [87]. In contrast, in a recent work it has been reported that inhibition of PI3K/Akt, but 
not of the downstream effector mTOR/raptor, during LCMV infection impaired budding and, at a 
lesser extent, RNA synthesis but not virus entry. Moreover, inhibition of PI3K/Akt reduced virus 
budding mediated by the matrix protein Z in a dose- dependent manner, suggesting the involvement of 
this cellular pathway in virus budding [88]. This apparent discrepancy about the involvement of PI3K 
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in LCMV entry may be ascribed to differences in LCMV strains employed for each report as well as to 
the different mechanisms of action of PI3K inhibitors used by both groups. Noticeably, Urata et al., 
demonstrated that BEZ-235, a PI3K inhibitor currently in cancer clinical trials, inhibited LCMV 
multiplication in cultured cells, reinforcing the good perspectives of cell-targeted agents in general and 
PI3K blockade in particular for arenavirus chemotherapy [88]. 
Interestingly, modulation of PI3K/Akt pathway was observed in CD8+ T cells during acute LCMV 
infection. In vivo phosphorylation levels of Akt, mTOR and FoxO1/O3, a critical regulator of T cell 
homeostasis activated by PI3K/Akt pathway, showed dynamic alterations during the course of 
infection: while Akt activation correlated with mTOR activity, no correlation was observed in 
FoxO1/O3 phosphorylation, inhibiting thus apoptosis of infected lymphocytes [89].  
As mentioned above, the comparison of signaling proteins regulated during macrophage infection 
with attenuated or virulent strains of PICV also allowed detect a differential response to each strain in 
three of the central signaling networks involving p53, c-Myc, and Akt, respectively [28]. Further 
studies revealed that macrophages isolated from guinea pigs infected with the P2 or P18 strain of PICV 
showed differential phosphorylation status of ERK [29], a component of the RAF-MEK-ERK1/2 
signaling pathway, other central route that regulates many cellular functions related to virus 
multiplication [90]. Although this pathway controls cell differentiation and proliferation leading to 
changes in gene expression, cell metabolism and apoptosis, little is known about its modulation by 
arenaviruses. In this regard, increase in ERK phosphorylation has been reported during PICV 
multiplication [91]. On the contrary, LASV infection impaired MEK/ERK activation after virus 
binding to its receptor [92].  
The trafficking mechanism of arenavirus is also an important point to be considered as a possible 
cellular target [93]. Upon binding receptor, endosomal acidification is a mandatory step for 
internalization of either New or Old world arenaviruses [94–97], although cellular receptor and hence 
the trafficking mechanisms are different. In case of LCMV and LASV, virus internalization is 
cholesterol-dependent but is independent of clathrin, caveolin, and dynamin. On the other hand the 
proteins Rab-5 and Rab-7 are partially required while ARF6, flotillin and actin would not to be 
necessary for LCMV and LASV entry [98–101]. On the contrary for the New World arenaviruses 
JUNV and PICV, virus internalization is clathrin- and dynamin-dependent but is partially dependent of 
cholesterol and independent of caveola. The proteins Eps15, Rab-5 and Rab-7 have also been shown 
necessary for both viruses [102–104]. In this regard, although novel approaches have been evaluated 
for antiviral drug development [105], the possibility to consider inhibition of kinases participating in 
the internalization process remains in the speculative field [106]. 
In conclusion, the modulation of survival signaling pathways is a critical event in the replication 
cycle of arenavirus. Given that these pathways are highly involved in the cell deregulation that occurs 
during cancer, much progress has been obtained in the development of potential chemotherapy agents 
against different components of these pathways that might be used as anti-arenaviral drugs.  
4.2. Kinases and Interferon 
The host immune response has been widely accepted to be one of the essential factors to determine 
the outcome of LCMV infection in mice [107]. From many of these studies it can be concluded that 
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viral modulation of phosphorylation of proteins involved in the IFN response is a key event to  
explain pathogenicity.  
Type I interferon (IFN-I) has been pointed out as an important factor that may have beneficial or 
detrimental consequences during LCMV infection of mouse [108]. On this basis, it has been 
demonstrated that inhibition of the innate immune response, mainly supported by the production of 
IFN, is necessary for the establishment of viral persistence in the mouse [109]. In vitro infection of 
several cell types by different arenaviruses showed the induction of IFN-I [110,111]. It has been 
reported that LCMV nucleoprotein negatively modulates IFN production in persistently infected A549 
cells by inhibiting nuclear translocation of the interferon regulatory factor 3 (IRF-3) [112]. This 
property has been also demonstrated for nucleoproteins of several representatives of New and Old 
World arenaviruses except for Tacaribe virus nucleoprotein [113]. LCMV nucleoprotein is able to 
interact with the IκB kinase (IKK)-related kinase IKKε leading to a loss of its phosphorylation activity 
towards IRF-3 [114]. At the same time, LCMV nucleoprotein is able to interfere with the nuclear 
translocation of the nuclear factor kappa B (NF-κ B) suggesting a multi-factorial role of this protein in 
the modulation of innate immune response and inflammation [115]. Also, Z protein from New World 
arenaviruses, but not from Old World members, antagonize IFN response by binding to the retinoic 
acid-inducible gene I (RIG-I) and inhibiting downstream activation of IFN-I expression signaling 
pathway [116]. 
One of the main mechanisms mediated by IFN and employed by cells to restrict viral infection is 
the up-regulation of the protein kinase R (PKR), which is activated by double-stranded RNA, a species 
that can be readily detected during the replication of many viruses. PKR expression is augmented 
during the IFN response and, in the case of infection, it phosphorylates the α subunit of eukaryotic 
translation initiation factor 2 (eIF2α), resulting in the blockage of cap dependent translation and 
impairment of the bulk of cellular protein synthesis and in many cases, viral protein synthesis as  
well [117]. At the same time, phosphorylation of eIF2α leads to the formation of stress granules, 
cytoplasmic aggregates that contain pre-initiation complexes that accumulate as a consequence of 
translation blockage. Many viruses can modulate eIF2α phosphorylation in order to counteract cell 
restriction [118]. On this line, it has been reported that JUNV is able to impair eIF2α phosphorylation 
upon stressing of infected Vero cells with sodium arsenite. Both, the nucleoprotein and the 
glycoprotein precursor were able to maintain low eIF2α phosphorylation levels, similar to those 
observed for control cells [119]. Although the mechanism through which arsenite induces eIF2α 
phosphorylation is under discussion, PKR may be one of the kinase targets for this drug [120]. 
Another point that might be considered as a prospective target for anti-arenaviral therapy is the 
Toll-like receptor 2 (TLR2) pathway that activates host defense mechanisms in order to prevent and 
eradicate infections and participates in the generation of the adaptive immune response [121]. Several 
years ago, Zhou et al., studied the role of TLR2 and myeloid differentiation factor 88 (MyD88) during 
an LCMV infection and demonstrated that TLR-mediated responses are necessary for an efficient 
innate immune response against this virus and that MyD88 would be of crucial importance for the 
maturation and activation of virus-specific CD8 (+) T cells [122]. Further studies revealed that LCMV 
infection of glial cells leads to the production of inflammatory chemokines, such as MCP-1, RANTES 
and TNF-alpha in a TLR2-MyD88 dependent manner [123]. On this perspective, a comprehensive 
study of prospective inhibitors of TLR2 signaling described the characterization of one of the active 
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compounds that also exhibited antiviral properties against LCMV, suggesting that this approach  
may be a promising tool for anti-arenaviral therapy [124]. It should be emphasized that the studies 
mentioned above were performed with the Armstrong strain of LCMV. Recent findings demonstrate 
that the WE strain of LCMV and LASV, both able to induce a fatal disease in rhesus macaques, 
suppressed pro-inflammatory cytokine responses that depend on TLR2. By contrast, nonpathogenic 
Mopeia arenavirus is able to activate TLR2 pathway, as described for the Armstrong strain of  
LCMV [125]. Similar results were reported for JUNV infection of murine macrophages, where 
expression of the TNF-alpha and beta IFN through a TLR2 pathway are activated by the viral 
glycoproteins [110]. 
In view of the results obtained to the present, impairment/disruption of innate immune response 
would be a key parameter that controls arenavirus pathogenicity. This approach deserves further 
investigation in order to determine if kinases involved in the modulation of IFN production/response 
would be attractive targets for antiviral therapy. 
5. Intrinsic Antiviral Resistance  
Intrinsic antiviral resistance, also known as viral restriction factors or intrinsic immunity, is a more 
recently described antiviral defense. Unlike acquired immunity and cytokine mediated innate 
immunity, intrinsic resistance functions through constitutively expressed cellular proteins that restrict 
virus replication within an individual infected cell [126,127]. Intrinsic resistance involves diverse 
proteins and mechanisms, depending on the particular virus. This group of proteins with potent 
antiviral properties is also induced by IFN-I [128] and comprised unrelated proteins like viperin and 
tetherin, among others [129–131].  
In this context, it has been reported that components of nuclear structures known as promyelocytic 
leukemia protein nuclear bodies (PML NBs) contribute to intrinsic resistance against a variety of DNA 
and RNA viruses, including arenaviruses [132]. PML NBs are macromolecular protein assemblies 
implicated in key cellular functions including cell cycle progression, DNA damage response, 
transcriptional regulation and apoptosis, but the precise biochemical function of PML NBs in these 
processes is not known [133,134]. PML NBs range in size from 0.2 to 1.2 μm in diameter [135] and 
their number and distribution vary considerably depending on cell type, cell cycle and cell condition, 
but typically between 10 and 20 PML NBs can be found per nucleus [136].  
Interestingly, PML NBs have been shown to contribute to innate defense against a broad  
range of viruses, and it has been reported that IFN treatment increases the number and size of PML 
NBs [137–139]. In turn, many viruses encode products that modify or eliminate PML NBs in cultured 
cells [132]. In particular for arenaviruses, it has been reported that LCMV influences the distribution of 
PML NBs through the specific interaction of the arenaviral Z protein and PML to form large bodies 
primarily in the cytoplasm of infected cells. Transient transfection and co-immunoprecipitation studies 
indicated that Z alone is sufficient to redistribute PML to the cytoplasm [140], whereas Z protein 
unfolded and inactivated by the effect of a zinc finger reactive compound failed to modify the 
distribution pattern of PML NBs components [141]. Moreover, the pro-apoptotic activity of PML in 
LCMV infected cells is mediated through the PML zinc binding region and the viral attack of PML 
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NBs would allow the virus to deregulate host cell apoptotic machinery in order to establish chronic 
infection [142].  
More importantly, another report has described that LCMV multiplication in PML −/− murine 
embryonic fibroblasts (MEF) exceeds virus production in PML +/+ MEF [116], and that in vivo  
PML deficiency renders mice more susceptible to different viral infections, such as vesicular  
stomatitis virus, encephalomyocarditis virus and LCMV infection, resulting in an increased viral  
replication [144,145]. 
Figure 2. (a) Effect of PML on infectious particle production. Control-siRNAs,  
PML-siRNAs and pcDNA-PML transfected A549 cells were infected with an attenuated 
strain of JUNV. At 24 h post infection (p.i.) viral yields were determined by a standard 
plaque assay; (b) Determination of PML-mRNA expression levels. JUNV infected A549 
cells were harvested at 24 h p.i. for qRT-PCR. PML-mRNA expression was represented as 
fold difference relative to mock infected cells and normalized to β-actin-mRNA; (c) Effect 
of JUNV infection on PML-NBs distribution. JUNV infected A549 cells were fixed 24 h p.i. 
and a double immunofluorescence was performed using monoclonal anti-nucleoprotein 
antibody visualized by fluorescein isothiocyanate and monoclonal anti-PML antibody 
visualized by tetramethyl rhodamine isothiocyanate. Cell nuclei were stained with  
4',6-diamidino-2-phenylindole (DAPI) (400X).  
 
In order to expand these studies, the antiviral role of PML NBs in JUNV multiplication was 
explored by determining the impact of PML silencing with specific siRNAs on infectious particle 
production. The virus yield observed in PML-silenced A549 cells was 4-fold higher than virus yield 
obtained in A549 control-siRNAs transfected cells (Figure 2a). The effective silencing of PML was 
confirmed by qRT-PCR (not shown), and, as seen, rendered these cells more susceptible to JUNV 
infection. To complement these findings, A549 cells were transfected with a PML encoding plasmid 
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(pcDNA-PML), and then infected with JUNV. It was observed that PML overexpression induced 
partial resistance to JUNV multiplication, as 50% inhibition on virus yield was obtained (Figure 2a). 
The restrictive role of PML in JUNV infection was also inferred through the determination of  
PML-mRNA by qRT-PCR in uninfected and JUNV infected cells. As seen in Figure 2b, JUNV 
infection produced more than 10-fold increase in PML-mRNA expression relative to control A549 
cells, confirming the contribution of PML to cellular antiviral defense against JUNV multiplication. 
Finally, confocal images of a A549 cell culture infected with JUNV illustrate the differential PML 
pattern between viral antigen-negative and viral antigen-positive cells (Figure 2c). Cells negative for 
JUNV antigen expression showed the typical punctuate pattern of PML NBs. In contrast, in cells 
expressing JUNV antigen a dramatic disruption of PML NBs was observed, with a marked efflux of 
PML protein from the nucleus to the cytoplasm, remaining only a diffuse fluorescence in the vicinity 
of the original nuclear structure.  
Altogether these results are the first evidence of PML contribution to a cellular antiviral response 
against an attenuated strain of JUNV; however, the mechanism by which PML inhibits this arenavirus 
still is unknown, and it is not clear that these effects observed in vitro could impact in viral disease. To 
further determine the biological impact of PML on JUNV replication, it will be necessary to look at the 
ability of arenaviruses to persist or cause disease in PML-knock down animals.  
It seems that the constitutive expression of PML would allow for immediate antiviral activity of this 
molecule, an effect which could be potentiated upon upregulation through IFN, or indirectly participate 
in the IFN-mediated upregulation of known or yet unknown IFN-regulated proteins with antiviral 
activity. Future studies with extensive and detailed molecular work will be needed to dissect this large 
array of potentially redundant and parallel pathways.  
6. Conclusions and Future Perspectives 
The alternative of cellular targets for antiviral chemotherapy against arenaviruses is at the initial 
phase of development, intending to identify the more appropriate virus-host cell interactions for an 
accurate blockade of infection regarding effectiveness and selectivity. As it was commented here, 
several host factors and also molecules directed to them have just been characterized in vitro and 
represent a promising starting point for future development. The innovative technologies of reverse 
genetics suitable for drug targeting by HTS, recently developed for arenaviruses, in combination with 
the analysis of transcriptome profiles of infected cells open new avenues in this field and may lead in 
the near future to an accelerated identification of novel key host factors in regulatory networks 
important for virus propagation. However challenges remain to be investigated in the next years about 
the real biological impact of this cell-based strategy for prophylaxis and treatment of the human 
disease, by the crucial testing of these indirect antiviral agents in adequate animal models. Those 
candidate drugs in clinical use or in an advanced stage of development for other diseases present the 
additional advantage of the knowledge of their toxicological and pharmacological profile. But also the 
novel molecules targeted to cellular pathways still not evaluated in vivo and found effective inhibitors 
in vitro assays represent an attractive starting point for in vivo testing, given the perspective of a broad-
spectrum activity against HF arenaviruses in continued and growing emergency.  
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